Francisca Vicente, Bahne Stechmann, Jeanette Hammer Andersen, Wolfgang Fecke, Jordi Quintana, José Brea, María J. Vicent, Sarka Simova, Lari Lehtiö, Mar Orzáez, Heiko Lickert, Dace Rasina, Kamil Paruch, Martin Neuenschwander, Zbigniew J. Leśnikowski, Antonio Pineda-Lucena, Mads Hartvig Clausen, Piotr Zielenkiewicz, Luca Laraia, Oscar Aubi, Stefan Krauss, Petr Bartunek, Faranak Nami, Jordi Mestres, Jens Peter von Kries, Philip Gribbon, Bastien Cautain, Aigars Jirgensons, Bernhard Ellinger, Philip Brennecke, Jacek L. Kolanowski, Ursula Bilitewski, Edgar Specker, Espen Hansen, Mark Brönstrup, Aurora Martinez, Olga Genilloud, Radosław Pilarski, Kjetil Taskén, Johannes Landskron, Marc Nazaré, Katja Herzog, Universidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica, Universidade de Santiago de Compostela. Centro de Investigación en Medicina Molecular e Enfermidades Crónicas, and Publica
Compound screening in biological assays and subsequent optimization of hits is indispensable for the development of new molecular research tools and drug candidates. To facilitate such discoveries, the European Research Infrastructure EU-OPENSCREEN was founded recently with the support of its member countries and the European Commission. Its distributed character harnesses complementary knowledge, expertise, and instrumentation in the discipline of chemical biology from 20 European partners, and its open working model ensures that academia and industry can readily access EU-OPENSCREEN’s compound collection, equipment, and generated data. To demonstrate the power of this collaborative approach, this perspective article highlights recent projects from EU-OPENSCREEN partner institutions. These studies yielded (1) 2-aminoquinazolin-4(3H)-ones as potential lead structures for new antimalarial drugs, (2) a novel lipodepsipeptide specifically inducing apoptosis in cells deficient for the pVHL tumor suppressor, (3) small-molecule-based ROCK inhibitors that induce definitive endoderm formation and can potentially be used for regenerative medicine, (4) potential pharmacological chaperones for inborn errors of metabolism and a familiar form of acute myeloid leukemia (AML), and (5) novel tankyrase inhibitors that entered a lead-to-candidate program. Collectively, these findings highlight the benefits of small-molecule screening, the plethora of assay designs, and the close connection between screening and medicinal chemistry within EU-OPENSCREEN. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: NOR-OPENSCREEN, funded by the Research Council of Norway (RCN) and the K.G. Jebsen Centre for Neuropsychiatric Disorders, for financial support (to A.M.). The Danish Research Infrastructure for Chemical Biology, DK-OPENSCREEN, acknowledges financial support from the Ministry of Higher Education and Science (grant case no. 5072-00019B), the Technical University of Denmark, and the other contributing universities. The Latvian Institute of Organic Synthesis acknowledges the European Regional Development Fund (agreement no. 1.1.1.1/16/A/290) for financial support. L.L. acknowledges the Academy of Finland (grant nos. 287063 and 294085) and the Jane and Aatos Erkko Foundation for funding. EU-OPENSCREEN acknowledges its member and observer states for funding and support. P. Bartunek acknowledges MEYS (LO1220 and LM2015063) for funding. P.G. and H.L. acknowledge funding from the German Federal Ministry of Education and Research. J.L.K. and R.P. acknowledge financial support from the Polish Ministry of Science and Higher Education (KNOW program and POL-OPENSCREEN project number 401086). M.J.V. acknowledges the European Regional Development Fund and the Conselleria de Sanitat Universal i Salut Pública (Generalitat Valenciana, GVA) SI